Host directed therapies for tuberculous meningitis

Simple item page
dc.contributor.authorDavis, Angharad G.en_ZA
dc.contributor.authorDonovan, Josephen_ZA
dc.contributor.authorBremer, Mariseen_ZA
dc.contributor.authorVan Toorn, Ronalden_ZA
dc.contributor.authorSchoeman, Johanen_ZA
dc.contributor.authorDadabhoy, Aribaen_ZA
dc.contributor.authorLai, Rachel P. J.en_ZA
dc.contributor.authorCresswell, Fiona V.en_ZA
dc.contributor.authorBoulware, David R.en_ZA
dc.contributor.authorWilkinson, Robert J.en_ZA
dc.contributor.authorThuong, Nguyen Thuy Thuongen_ZA
dc.contributor.authorThwaites, Guy E.en_ZA
dc.contributor.authorBahr, Nathan C.en_ZA
dc.contributor.authorTuberculous Meningitis International Research Consortiumen_ZA
dc.date.accessioned2022-04-12T12:29:00Z
dc.date.available2022-04-12T12:29:00Z
dc.date.issued2020-07-01
dc.descriptionCITATION: Davis, Angharad G. et al. 2020. Host directed therapies for tuberculous meningitis. Wellcome Open Research, 5:292, doi:10.12688/wellcomeopenres.16474.2.en_ZA
dc.descriptionThe original publication is available at: https://pubmed.ncbi.nlm.nih.gov
dc.description.abstractENGLISH ABSTRACT: A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality. However, there is no evidence dexamethasone reduces morbidity, how it reduces mortality is uncertain, and it has no proven benefit in HIV co-infected individuals. Further research on these aspects of its use, as well as alternative HDTs such as aspirin, thalidomide and other immunomodulatory drugs is needed. Based on new knowledge from pathogenesis studies, repurposed therapeutics which act upon small molecule drug targets may also have a role in TBM. Here we review existing literature investigating HDTs in TBM, and propose new rationale for the use of novel and repurposed drugs. We also discuss host variable responses and evidence to support a personalised approach to HDTs in TBM.en_ZA
dc.description.versionPublisher's version
dc.format.extent22 pagesen_ZA
dc.identifier.citationDavis, Angharad G. et al. 2020. Host directed therapies for tuberculous meningitis. Wellcome Open Research, 5:292, doi:10.12688/wellcomeopenres.16474.2en_ZA
dc.identifier.otherdoi:10.12688/wellcomeopenres.16474.2
dc.identifier.urihttp://hdl.handle.net/10019.1/124449
dc.language.isoen_ZAen_ZA
dc.publisherWellcome Trusten_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectTuberculous meningitis -- Therapeuticsen_ZA
dc.subjectHost directed therapiesen_ZA
dc.subjectMeningitis, Tuberculousen_ZA
dc.subjectDexamethasoneen_ZA
dc.titleHost directed therapies for tuberculous meningitisen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
davis_host_2020.pdf
Size:
1.55 MB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Paediatrics and Child Health)